This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the company that markets lutetium-177 DOTATATE has informed us that they are not able to provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect.
 
Status Suspended
Decision Selected
Process STA pre-2018
ID number 857

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors Imaging Equipment (lutetium-177 DOTATATE)
Others Department of Health
  NHS England
  Welsh Government
Professional groups British Nuclear Medicine Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiographers
  UK and Ireland Neuroendocrine Tumour Society (UKI NETS)
Comparator companies Hospira UK - CAU not returned, not participating
  Ipsen - CAU not returned, not participating
  Novartis Pharmaceuticals UK - CAU not returned, not participating
  Sun Pharmaceuticals UK - CAU not returned, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
25 August 2016 Invitation to participate
25 August 2016 Suspended. This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the company that markets lutetium-177 DOTATATE has informed us that they are not able to provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect.
04 February 2016 Draft scope documents
14 January 2016 Referral

For further information on our processes and methods, please see our CHTE processes and methods manual